Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Vactech OY currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, though they are both situated within 1 distinct art unit. This suggests that while the technical subject matter is consistent enough to stay in 1 unit, the company must manage the individual styles of 2 different examiners. Practitioners can use the shared 1 art unit to maintain consistency in technical definitions across the 2 filings.
The busiest examiner for the portfolio is SIFFORD, JEFFREY MARK, who is responsible for 1 busiest examiner pending action. Practitioners should prepare for the specific nuances of the Biotechnology & Pharmaceuticals field while addressing the 2 pending office actions across these separate examiner interactions. Managing 2 distinct examiners within the 1 art unit requires a coordinated strategy. The resolution of the 1 busiest examiner pending action will be a key step in advancing the pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703256 | Coxsackievirus B Compositions and Methods Of Use Thereof | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | CHEN, STACY BROWN | 11d overdue |
| 18703256 | Coxsackievirus B Compositions and Methods Of Use Thereof | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703256 | Coxsackievirus B Compositions and Methods Of Use Thereof | SIFFORD, JEFFREY MARK | — | §101§103§112 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18418050 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | CHEN, STACY BROWN | 1672 | §112 | Final Rejection | 11d overdue | Pending | Jan 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial